Contact this trialFirst, we need to learn more about you.
Sphingosine-1-Phosphate Receptor Modulator
Ofatumumab + Siponimod vs Fingolimod for Pediatric Multiple Sclerosis
Recruiting1 awardPhase 3
Tampa, Florida
This trial showed that ofatumumab and siponimod are more effective and safer than fingolimod in treating multiple sclerosis in children.
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.